Dordaviprone is a first-in-class small molecule imipridone. On August 6, 2025, dordaviprone was granted accelerated approval by the FDA.[L53838] It is used to treat patients with diffuse midline glioma harboring an H3 K27M mutation.[L53833] Dordaviprone was initially studied as an anticancer agent that induces TNF-Related Apoptosis-Inducing Ligand (TRAIL).[A274391] Dordaviprone has several modes of action, including the activation of mitochondrial caseinolytic protease P (ClpP), antagonism of the dopamine D2 receptor,[L53833] activation of Activating Transcription Factor 4 (ATF4), and induction of endoplasmic reticulum (ER) stress response.[A274391]
Dordaviprone is indicated for the treatment of adult and pediatric patients 1 year of age and older with diffuse midline glioma harboring an H3 K27M mutation with progressive disease following prior therapy. This indication is approved under accelerated approval based on overall response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s).[L53833]
Drug Info/Drug Targets: DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Knox C, Law V, Jewison
T, Liu P, Ly S, Frolkis A, Pon A, Banco K, Mak C, Neveu V, Djoumbou Y, Eisner R, Guo AC, Wishart DS.
Nucleic Acids Res. 2011 Jan; 39 (Database issue):D1035-41. | PMID:21059682
